We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Drug-Drug Interactions in Patients Co-infected With HCV and HIV

Yuichi Nozaki, MD, PhD1; Mikio Yanase, MD, PhD1; Naohiko Masaki, MD, PhD2
[+] Author Affiliations
1Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
2Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Tokyo, Japan
JAMA. 2015;314(2):186. doi:10.1001/jama.2015.6618.
Text Size: A A A
Published online


To the Editor In a small pilot study, Dr Osinusi and colleagues1 reported the safety and high sustained virologic response rate for combined treatment using ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, with sofosbuvir, an HCV NS5B polymerase inhibitor, in previously untreated, noncirrhotic patients with HCV genotype 1 and human immunodeficiency virus (HIV) co-infection. This study analyzed the changes in HIV parameters, such as HIV RNA level or CD4 T-lymphocyte count, and in renal function, such as serum creatinine level or estimated glomerular filtration rate.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




July 14, 2015
Anu Osinusi, MD, MPH; Kerry Townsend, BA; Shyam Kottilil, MD, PhD
1Institute of Human Virology, University of Maryland, Baltimore
2Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
JAMA. 2015;314(2):186-187. doi:10.1001/jama.2015.6621.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...